HealthKey vs Isomorphic Labs

HealthKey's capability is narrow and operational: connect to an EHR, encode a protocol's inclusion/exclusion criteria, and let the platform scan records daily for eligible patients. Matches come back with chart evidence so coordinators verify at a glance, ranked by likelihood to enroll, delivered to a dashboard and inbox. The recent case studies show the mechanism at scale — 4,269 patients screened against 24 criteria in a cardiovascular trial, 12,004 patients and 4.6M records scanned for an obesity study that surfaced 23 verified-eligible patients, and a 42-criteria bimekizumab protocol yielding 14 qualified patients in 11 days. The claim that one patient was missed by other platforms speaks to sensitivity, not breadth.

Isomorphic Labs' capability is scientific and generative: a Drug Design Engine for designing novel molecules, predictive models for anticipating drug behavior, and end-to-end programs from target identification to lead optimization, built on and beyond the AlphaFold system. Its feature list describes research services, not software a coordinator logs into. The 2026 Johnson & Johnson collaboration applies this to multiple therapeutic targets; the bioresilience push applies it to biological threats. One automates chart review. The other tries to invent the molecule that chart review is enrolling for.

Both pages say contact sales, but the money models diverge sharply. HealthKey charges a success fee per enrolled patient, plus free implementation and protocol setup for a limited time and a one-week onboarding. That means a site's cash outlay is tied to a result it already wants — an enrolled patient — and the upfront risk is near zero. The medicine is in the fine print, which isn't public: the success fee per patient is undisclosed, and so is any minimum. For a site with fewer than 100 patients in its EHR, the economics likely never justify setup.

Isomorphic Labs doesn't price per unit at all. Its model is a research collaboration funded at partnership scale, which for a large pharma means seven- or eight-figure program commitments measured in years, not seats or enrollments. The 2026 Series B and the J&J deal signal the company funds itself through these collaborations. There is no self-service tier, no published rate card, and no path for a startup or a small site. Comparing their price tags is like comparing a plumber's call-out fee to a pharmaceutical R&D budget — both say 'contact us,' but only one of them is something you can buy next quarter.